This entry is a media-coverage repost of an Indianapolis Business Journal article covering BiomEdit’s operational progress as CPerf LLV* (BE-101), soon to be branded Optavant, approaches full USDA licensure and a targeted Q3 2026 commercial launch. The original article is a subscriber-only IBJ feature and is not reproduced here.
Indianapolis Business Journal · May 28, 2026
BiomEdit on the Move as First Product Nears Market
IBJ reports that CPerf LLV* (BE-101) (soon to be branded Optavant) is expected to reach commercial availability in Q3 2026 pending full USDA licensure, covering BiomEdit's operational progress.
*Clostridium Perfringens Alpha Toxin and NetB Antibody Fragment, Live Limosilactobacillus Vector